Core Insights - The company reported satisfactory Q3 results, leading to an upgrade of profit before tax by DKK 150 million, excluding special costs [1] - The CEO highlighted a strong inflow of new customers and progress in the merger of Codan and Alm. Brand, aiming to meet ambitious financial targets for 2025 [1][2] Financial Performance - Guidance for the insurance service result has been raised by DKK 100 million, now specified to DKK 1.75-1.85 billion [3] - Investment result guidance increased by DKK 50 million to DKK 300 million [3] - Q3 2025 insurance service result showed a profit of DKK 535 million, up from DKK 400 million, with a combined ratio improving to 82.2 from 85.7 [3] - Insurance revenue grew by 7.5% to DKK 3,006 million, driven by a 9.9% increase in Personal Lines premiums [3] - The underlying claims experience improved by 3.2 percentage points to 61.4, aided by favorable developments in Commercial Lines [3] - The expense ratio improved to 15.8 from 17.1, reflecting the group's cost-reduction objectives [3] - Synergy initiatives generated a positive accounting effect of DKK 158 million in Q3 2025, with expectations to realize over DKK 600 million in synergies for 2025 [3] - The investment result was satisfactory at DKK 66 million, with shares and bonds contributing positively [3] - Consolidated profit before tax reached DKK 452 million, up from DKK 376 million [3] - The company maintained a high SCR ratio of 254% in Q3 2025 based on PIM approval [3]

Core Points - Addex Therapeutics has issued 34,300,000 new registered shares at a nominal value of CHF 0.01, fully subscribed by its wholly-owned subsidiary, Addex Pharma S.A, to enhance future financing flexibility [1] - The total issued share capital has increased to CHF 2,186,544.96, with a total of 218,654,496 shares issued, while the number of outstanding shares remains unchanged [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [2] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [2] - Addex has partnered with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [2] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [2] - Additionally, Addex has invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]

Core Insights - The company reported significant profitability improvement in its Facility Services businesses, while the Circular Economy Business showed stable performance despite a slight decline in adjusted operating profit [3][4][11]. Financial Performance - For January to September 2025, net sales totaled EUR 571.4 million, a decrease of 0.9% compared to the previous year [6][13]. - Adjusted operating profit for the same period was EUR 37.7 million, up 15.5% from EUR 32.7 million in the previous year [6][13]. - The third quarter net sales were EUR 199.5 million, representing a year-on-year increase of 3.8% [10][17]. - Adjusted operating profit for the third quarter was EUR 20.1 million, slightly up from EUR 20.0 million in the previous year [10][17]. Business Segments Circular Economy Business - Net sales for the Circular Economy Business in January to September were EUR 315.5 million, down from EUR 318.6 million [19]. - Adjusted operating profit for this segment was EUR 31.1 million, a decline from EUR 33.0 million in the previous year [19]. - Demand for recycling and waste management services decreased, particularly in the construction industry [4][20]. Facility Services - Facility Services Finland reported net sales of EUR 170.2 million, down from EUR 179.2 million, but adjusted operating profit improved to EUR 11.1 million from EUR 6.8 million [26][27]. - Facility Services Sweden saw an increase in net sales to EUR 87.3 million from EUR 80.9 million, with adjusted operating results improving to a loss of EUR 2.9 million from a loss of EUR 6.0 million [29][30]. Outlook - The company estimates that net sales in 2025 will be at the same level as in the previous year, with adjusted operating profit projected to be between EUR 44 million and EUR 48 million [2][77]. Sustainability Performance - The company's carbon footprint decreased by 19% compared to the previous year, driven by the use of renewable fuels and investments in a low-emission fleet [8][45]. - Customer satisfaction reached an all-time high with a Net Promoter Score (NPS) of 41 [8][45]. Demerger Plans - The company is preparing for a partial demerger to separate its Circular Economy business into a new publicly listed company, with the plan approved by the Board of Directors on August 7, 2025 [9][75]. - The demerger is subject to approval at an Extraordinary General Meeting scheduled for December 4, 2025, with an effective date planned for December 31, 2025 [9][76].

Corbion Q3 2025 Interim Management Statement Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for the first nine months of 2025. Key highlights first nine months 2025: Organic sales growth:+1.2%(Q3: -2.2%) - Volume/mix:+1.7%(Q3: -1.5%) - Price:-0.5%(Q3: -0.7%)Sales€ 957.2 million(Q3: € 311.6 million)Adjusted EBITDA€ 156.3 million(Q3: € 49.7 million)Adjusted EBITDA organic growth+22.9% Operating profit € 91.4 ...

Issuer: Subsea 7 S.A.Ex. date: 29 October 2025Dividend amount: NOK 6.50Announced currency: Norwegian Krone Contact for investment community enquiries:Katherine TonksDirector, Investor RelationsTel +44 20 8210 5568ir@@subsea7.com This information is published in accordance with the requirements of the Continuing Obligations. ...

China Cultural Center in Madrid "Charm of Jiangsu" Cultural and Tourism Promotion Conference, along with the "Weaving Water in Silk, Eastern Elegance" Embroidery Art Exhibition "Charm of Jiangsu" Cultural and Tourism Promotion Conference, along with the "Weaving Water in Silk, Eastern Elegance" Embroidery Art Exhibition MADRID, Oct. 29, 2025 (GLOBE NEWSWIRE) -- On the afternoon of November 4, 2025, the "Charm of Jiangsu" Cultural and Tourism Promotion Conference, along with the "Weaving Water in Silk, Ea ...

Core Points - Equinor will commence the fourth tranche of its share buy-back programme for 2025 on 30 October 2025, with a total value of up to USD 1,266 million, including USD 417.8 million for market purchases [1][2] - The share buy-back programme aims to reduce the issued share capital of the company, with all shares purchased in the fourth tranche to be cancelled at the annual general meeting in May 2026 [4][8] - The maximum number of shares that can be purchased in the fourth tranche is 84 million, with 50,677,690 shares remaining available for purchase at the start of this tranche [5] Share Buy-Back Programme Details - The share buy-back programme for 2025 was announced in February 2025, with a total value of up to USD 5 billion, structured into tranches based on market conditions and balance sheet strength [2] - A non-discretionary agreement will be established with a third party to execute share repurchases independently of Equinor [2] - Future tranches after the fourth will be decided quarterly by the board, in line with the company's dividend policy [3] State Participation and Share Cancellation - An agreement with the Norwegian State ensures that the State will vote for the cancellation of shares purchased in the market at the annual general meeting in May 2026, maintaining its ownership share at 67% [6] - The price for the State's shares will be based on the volume-weighted average price paid by Equinor for market purchases, plus interest compensation [6] Trading and Compliance - Shares will be purchased on the Oslo Stock Exchange and potentially other venues within the EEA, adhering to applicable safe harbour conditions and regulations [7] - The company is obligated to disclose this information under the EU Market Abuse Regulation and Norwegian Securities Trading Act [8]

Group 1 - The cash dividend amount for Equinor for Q3 2025 is set at 0.37 USD per share [1] - The last day to include rights for the dividend is 13 February 2026 [1] - The ex-date for Oslo Børs is 16 February 2026, and for the New York Stock Exchange, it is 17 February 2026 [1] - The record date for the dividend is 17 February 2026 [1] - The payment date for the dividend is scheduled for 27 February 2026 [1] - The date of approval for the dividend is 28 October 2025 [1] - The cash dividend per share in NOK will be communicated on 23 February 2026 [1] Group 2 - The information is published in accordance with the Euronext Oslo Børs Continuing Obligations [2] - The disclosure is subject to the requirements of Section 5-12 in the Norwegian Securities Trading Act [2]

Financial Performance - Equinor reported an adjusted operating income of USD 6.21 billion and an adjusted net income of USD 0.93 billion for Q3 2025, leading to adjusted earnings per share of USD 0.37 [1][9] - The net operating income was USD 5.27 billion, down from USD 6.91 billion in the same quarter last year, impacted by net impairments of USD 754 million [10] - Cash flows from operating activities before taxes were USD 9.10 billion, with cash flow from operations after taxes paid at USD 5.33 billion [13] Production and Operational Highlights - Total equity production reached 2,130 mboe per day, a 7% increase from 1,984 mboe per day in Q3 2024 [3] - Strong operational performance on the Norwegian continental shelf (NCS) with a 9% production growth, particularly from the Johan Sverdrup and Johan Castberg fields [4][7] - The US segment saw a 29% increase in oil and gas production due to acquisitions and increased offshore production [5] Strategic Developments - Production commenced from the Bacalhau field in Brazil, the largest international offshore field developed by Equinor, expected to significantly contribute to earnings [2][16] - Successful exploration led to seven commercial discoveries on the NCS, enhancing Equinor's role as a reliable energy supplier to Europe [15] - The company decided to stop two early-phase electrification projects due to high abatement costs, while further developing the Grane-Balder energy project [18] Capital Distribution - A cash dividend of USD 0.37 per share was declared for Q3 2025, consistent with previous announcements [19] - The fourth tranche of the share buy-back program for 2025 will be up to USD 1.266 billion, completing a total capital distribution of around USD 9 billion for the year [20][21] Renewable Energy Contributions - Total power generation was 1.37 TWh, with the renewable portfolio contributing 0.91 TWh, a 34% increase year-over-year [8] - The company completed 18 offshore exploration wells on the NCS, resulting in seven commercial discoveries [8]

Financial Performance - Hepsor's consolidated revenue for Q3 2025 was 8.8 million euros, a decrease from 20.4 million euros in Q3 2024. For the first nine months of 2025, revenue increased to 30.9 million euros from 27.9 million euros in the same period of 2024 [1] - The net profit for Q3 2025 was 1.2 million euros, down from 2.7 million euros in Q3 2024. However, the net profit for the first nine months of 2025 rose to 1.5 million euros from 1.2 million euros in 9M 2024 [2] Property Transactions - The financial results were significantly impacted by the sale of properties to the joint venture Hepsor SOF OÜ, with a total transaction value of 9.0 million euros, generating a profit of 1.8 million euros recognized in Q2 and Q3 [3] Development Projects - A new residential development project in Riga at Starta 17 was added, planning to construct 255 new homes in several stages [6] - As of September 30, 2025, Hepsor had 10 residential development projects for sale, with 355 new homes and 453 m² of commercial space completed, of which 87% (309 homes) have been sold [7] - The Group has 374 new homes under construction, with 173 in Latvia and 201 in Estonia [8] Commercial Real Estate - Construction of the StokOfiss U34 multifunctional commercial building in Riga began in 2024, with a leasable area of 8,740 m². As of September 30, 2025, 70% of the leasable area was covered by lease agreements [9] Canadian Operations - Hepsor's Canadian operations focus on land-use planning for development projects, with investments in five projects. A recent decision by the Toronto City Council granted building rights for a development project, allowing for the construction of two residential towers [10] Future Outlook - Hepsor plans to commence construction of two development projects in Riga in Q4 2025 and launch four new projects in the first half of 2026 [11] - An investor meeting is scheduled for November 13 in Estonia and November 14 in Latvia to discuss financial results and future plans [11]